Comparing Cytotoxic Effects of 7-Prenyloxycoumarin Derivatives on Human Leukemia/Lymphoma Cells
Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 477
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ACPLMED21_031
تاریخ نمایه سازی: 6 آبان 1398
Abstract:
Introduction: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells with poor prognosis, which is mainly due to intrinsic chemoresistance and severe immunosuppression. ATLL shows a distinct geographical distribution that includes southwestern Japan, the Caribbean basin, part of central Africa and north eastern of Iran. 7-prenyloxycoumarins are natural compounds mainly found Rutaceae and Umbelliferae families with valuable pharmacological activities. To introduce a novel and more effective therapeutic modality against ATLL, we evaluated cytotoxic effects of two 7-prenyloxycoumarins on an ATLL cell line.Methods: Auraptene (AUR) and umbelliprenin (UMB) were synthesized by a reaction between 7-hydroxycoumarin and prenyl bromides, followed by column chromatography to be purified. Then, MT-2 cells were treated with 10 µg/ml AUR or UMB for 96 h, while cell treated with 0.2% DMSO were considered as control. For viability assessment of cells, resazurin was used and absorption was measured after 2 h at 600 nm.Results and conclusion: Quantitative assessment of cell viability revealed that 75.2% and 88.6% of cells were alive 4 days after administration of 10 µg/ml AUR and UMB, respectively. Since AUR induced more cell death, it could be considered as potent toxic agent, while UMB has the potential to be used in combinatorial modalities against ATLL.
Keywords:
Authors
Ramin Bagheri
Cancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Sciences, Iran
Mohamadreza Keramati
Cancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Sciences, Iran
Fatemeh B. Rassouli
Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran
Houshang Rafatpanah
Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran